• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24133 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for vascular access care]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for fall prevention]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence-based patient information on chronic obstructive airway diseases - Asthma]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: xanthine oxidase inhibitors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: treatment of comorbidities]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: test accuracy of various methods for diagnosing gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: lifestyle changes for gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: drug treatment of a gout attack]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: allopurinol versus febuxostat]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Technical support systems]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structured information on the initial diagnosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structural imaging]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Dementia care management]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Cognitive training / cognitive stimulation]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: timing of nutrition in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional interventions in chronic pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Evidence overview of therapeutic hypothermia]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence on orphan drugs]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evidence brief on the measures related to the reimbursement of blood glucose test strips]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Everolimus (Afinitor) for the treatment of renal cell carcinoma]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of vascular care in Alzheimer's disease]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the utility and indication of prostate biopsies with image fusion – magnetic resonance and transrectal ultrasound]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]
1998     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of the use of antidigoxin antibodies in the treatment of digitalis intoxication]
2018     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the ultrasonic flowmeter for verification of graft patency during coronary artery bypass grafting]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the tiered system of emergency structures in hospitals]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the scientific evidence on nipple-areola complex micropigmentation, requirements for its proper implementation and costs]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of the potential of real-time 3-dimensional echocardiography in the assessment of right ventricular function in adult congenital heart disease: comparison of RT-3D echo with MRI]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Canary Health Service [Evaluation of the lung cancer screening program]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the implementation of clinical guidelines in the Basque Country. Cluster randomized trial]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of the evidence on the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage heart failure]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the efficacy and safety of negative pressure in the treatment of chronic wounds]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the effectiveness of psychological intervention in the first psychotic episode by multidisciplinary treatment]
2023     Center for Drug Evaluation (CDE) [Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the effectiveness of hip and knee implant models used by the Spanish National Health System]
2009     Canary Health Service [Evaluation of the effectiveness and costs of Quantiferon-TB Gold for the diagnosis of latent tuberculosis infection in healthcare personnel]
2019     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the effectiveness and cost effectiveness of cardiac rehabilitation programs]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Evaluation of the Danish National Cancer Action Plan - status and future monitoring - summary and proposals for focus areas]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2005     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the benefits and harms of statins (with particular consideration of atorvastatin)]
2016     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of technologies allowing the induction of therapeutic hypothermia in patients who have suffered a cardiac arrest]
2003     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of techniques for detecting breast implant rupture]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Evaluation of taking mifepristone at home during a medical abortion]
2011     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of surrogate variables in oncology. Advanced and metastatic breast cancer]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of subcutaneous-lead implantable cardioverter-defibrillators]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Evaluation of several vaccination strategies against rotavirus in Spain. Safety, efficacy, effectiveness and efficiency]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of regular searches in the ICTRP Search Portal]
2021     Norwegian Institute of Public Health (NIPH) [Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]
2023     Canary Health Service [Evaluation of patient involvement in health technology assessment]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of optical coherence tomography in the diagnosis of age related macular degeneration compared with fluorescence angiography]
2010     Haute Autorite de sante (HAS) [Evaluation of negative-pressure wound therapy]
2011     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Evaluation of multiple technologies for chronic wounds and burns]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of mHealth-based technology for mobile applications]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of bariatric surgery (obesity surgery) versus conservative strategies in adult patients with morbid obesity]
2014     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of measures related to the prevention of multiple falls in hospitalized elderly people]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of l-caldesmon as biomarker for brain tumor monitoring]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Evaluation of implementation of foetal screening]
2024     Haute Autorite de sante (HAS) [Evaluation of high-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of genetic tests related to hearing loss and their role in neonatal population screening]
2016     Haute Autorite de sante (HAS) [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of ethylene oxide sterilant alternatives: plasma and ozone]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficiency of organizational models for stroke management (stroke units)]
2013     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficacy and safety of PET-CT (update)]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of early intervention programs in psychosis targeting adolescents and young adults]